vTv Therapeutics (VTVT) Sees Large Volume Increase Following Insider Buying Activity

Shares of vTv Therapeutics Inc (NASDAQ:VTVT) saw unusually-strong trading volume on Thursday following insider buying activity. Approximately 3,640,646 shares traded hands during trading, an increase of 7,228% from the previous session’s volume of 49,684 shares.The stock last traded at $5.56 and had previously closed at $4.05.

Specifically, major shareholder Ronald O. Perelman acquired 50,000 shares of vTv Therapeutics stock in a transaction on Tuesday, December 26th. The shares were bought at an average cost of $4.03 per share, for a total transaction of $201,500.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Paul G. Savas acquired 15,000 shares of vTv Therapeutics stock in a transaction on Thursday, December 7th. The shares were purchased at an average price of $4.56 per share, for a total transaction of $68,400.00. Following the completion of the acquisition, the director now directly owns 81,781 shares in the company, valued at $372,921.36. The disclosure for this purchase can be found here. Company insiders own 0.80% of the company’s stock.

Several research analysts have commented on VTVT shares. Zacks Investment Research upgraded vTv Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a report on Saturday, September 30th. Citigroup restated an “add” rating on shares of vTv Therapeutics in a report on Wednesday, November 8th. Stifel Nicolaus restated a “buy” rating and set a $12.00 price objective on shares of vTv Therapeutics in a report on Friday, November 3rd. Finally, Canaccord Genuity set a $15.00 price target on vTv Therapeutics and gave the company a “buy” rating in a report on Thursday, December 21st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. vTv Therapeutics currently has an average rating of “Buy” and an average target price of $14.10.

The stock has a market capitalization of $135.19 and a price-to-earnings ratio of -3.39.

Several large investors have recently made changes to their positions in VTVT. Renaissance Technologies LLC increased its holdings in shares of vTv Therapeutics by 4.8% in the 1st quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock valued at $418,000 after acquiring an additional 2,900 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of vTv Therapeutics by 62.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock valued at $1,313,000 after acquiring an additional 101,850 shares during the period. State Street Corp increased its holdings in shares of vTv Therapeutics by 2.1% in the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 1,976 shares during the period. Finally, JPMorgan Chase & Co. purchased a new position in shares of vTv Therapeutics in the 3rd quarter valued at $481,000. Institutional investors and hedge funds own 10.42% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Week Herald and is owned by of Week Herald. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://weekherald.com/2017/12/29/vtv-therapeutics-vtvt-sees-large-volume-increase-following-insider-buying-activity.html.

About vTv Therapeutics

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply